220 related articles for article (PubMed ID: 22155828)
41. High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure.
Tyagi RK; Gleeson PJ; Arnold L; Tahar R; Prieur E; Decosterd L; Pérignon JL; Olliaro P; Druilhe P
BMC Med; 2018 Oct; 16(1):181. PubMed ID: 30269689
[TBL] [Abstract][Full Text] [Related]
42. NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria.
Bertinaria M; Orjuela-Sanchez P; Marini E; Guglielmo S; Hofer A; Martins YC; Zanini GM; Frangos JA; Gasco A; Fruttero R; Carvalho LJ
J Med Chem; 2015 Oct; 58(19):7895-9. PubMed ID: 26367273
[TBL] [Abstract][Full Text] [Related]
43. IL-4 Treatment Mitigates Experimental Cerebral Malaria by Reducing Parasitemia, Dampening Inflammation, and Lessening the Cytotoxicity of T Cells.
Wu X; Thylur RP; Dayanand KK; Punnath K; Norbury CC; Gowda DC
J Immunol; 2021 Jan; 206(1):118-131. PubMed ID: 33239419
[TBL] [Abstract][Full Text] [Related]
44. Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.
DellaValle B; Hempel C; Staalsoe T; Johansen FF; Kurtzhals JA
Malar J; 2016 Aug; 15(1):427. PubMed ID: 27554094
[TBL] [Abstract][Full Text] [Related]
45. Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy.
Capela R; Cabal GG; Rosenthal PJ; Gut J; Mota MM; Moreira R; Lopes F; Prudêncio M
Antimicrob Agents Chemother; 2011 Oct; 55(10):4698-706. PubMed ID: 21807973
[TBL] [Abstract][Full Text] [Related]
46. Protective activity of biflavanones from Garcinia kola against Plasmodium infection.
Konziase B
J Ethnopharmacol; 2015 Aug; 172():214-8. PubMed ID: 26129936
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the antimalarial activity of new compounds against Plasmodium falciparum in vitro, and Plasmodium berghei in vivo.
Tedlaouti F; Gasquet M; Delmas F; Timon-David P; Madadi NE; Vanelle P; Maldonado J
J Pharm Belg; 1990; 45(5):306-10. PubMed ID: 2086754
[TBL] [Abstract][Full Text] [Related]
48. A central role for free heme in the pathogenesis of severe malaria: the missing link?
Ferreira A; Balla J; Jeney V; Balla G; Soares MP
J Mol Med (Berl); 2008 Oct; 86(10):1097-111. PubMed ID: 18641963
[TBL] [Abstract][Full Text] [Related]
49. MK-4815, a potential new oral agent for treatment of malaria.
Powles MA; Allocco J; Yeung L; Nare B; Liberator P; Schmatz D
Antimicrob Agents Chemother; 2012 May; 56(5):2414-9. PubMed ID: 22314528
[TBL] [Abstract][Full Text] [Related]
50. Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.
Howland SW; Ng GX; Chia SK; Rénia L
Parasite Immunol; 2015 Nov; 37(11):599-604. PubMed ID: 26366636
[TBL] [Abstract][Full Text] [Related]
51. A new class of phenazines with activity against a chloroquine resistant Plasmodium falciparum strain and antimicrobial activity.
Hussain H; Specht S; Sarite SR; Saeftel M; Hoerauf A; Schulz B; Krohn K
J Med Chem; 2011 Jul; 54(13):4913-7. PubMed ID: 21591758
[TBL] [Abstract][Full Text] [Related]
52. Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice.
Postma NS; Crommelin DJ; Eling WM; Zuidema J
J Pharmacol Exp Ther; 1999 Jan; 288(1):114-20. PubMed ID: 9862761
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and antimalarial activity of trifluoromethylartemisinin-mefloquine dual molecules.
Grellepois F; Grellier P; Bonnet-Delpon D; Bégué JP
Chembiochem; 2005 Apr; 6(4):648-52. PubMed ID: 15723441
[No Abstract] [Full Text] [Related]
54. UK malaria treatment guidelines.
Lalloo DG; Shingadia D; Pasvol G; Chiodini PL; Whitty CJ; Beeching NJ; Hill DR; Warrell DA; Bannister BA;
J Infect; 2007 Feb; 54(2):111-21. PubMed ID: 17215045
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and antimalarial efficacy of aza-fused rhodacyanines in vitro and in the P. berghei mouse model.
Takasu K; Pudhom K; Kaiser M; Brun R; Ihara M
J Med Chem; 2006 Jul; 49(15):4795-8. PubMed ID: 16854088
[TBL] [Abstract][Full Text] [Related]
56. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.
Reis PA; Comim CM; Hermani F; Silva B; Barichello T; Portella AC; Gomes FC; Sab IM; Frutuoso VS; Oliveira MF; Bozza PT; Bozza FA; Dal-Pizzol F; Zimmerman GA; Quevedo J; Castro-Faria-Neto HC
PLoS Pathog; 2010 Jun; 6(6):e1000963. PubMed ID: 20585569
[TBL] [Abstract][Full Text] [Related]
57. Synthetic angiotensin II peptide derivatives confer protection against cerebral and severe non-cerebral malaria in murine models.
Silva AF; Torres MDT; Silva LS; Alves FL; Miranda A; Oliveira VX; de la Fuente-Nunez C; Pinheiro AAS
Sci Rep; 2024 Feb; 14(1):4682. PubMed ID: 38409185
[TBL] [Abstract][Full Text] [Related]
58. Chloroquine-containing organoruthenium complexes are fast-acting multistage antimalarial agents.
Macedo TS; Colina-Vegas L; DA Paixão M; Navarro M; Barreto BC; Oliveira PC; Macambira SG; Machado M; Prudêncio M; D'Alessandro S; Basilico N; Moreira DR; Batista AA; Soares MB
Parasitology; 2016 Oct; 143(12):1543-56. PubMed ID: 27439976
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate.
de Pilla Varotti F; Botelho AC; Andrade AA; de Paula RC; Fagundes EM; Valverde A; Mayer LM; Mendonça JS; de Souza MV; Boechat N; Krettli AU
Antimicrob Agents Chemother; 2008 Nov; 52(11):3868-74. PubMed ID: 18710907
[TBL] [Abstract][Full Text] [Related]
60. A phenolic glycoside from Flacourtia indica induces heme mediated oxidative stress in Plasmodium falciparum and attenuates malaria pathogenesis in mice.
Singh SV; Manhas A; Singh SP; Mishra S; Tiwari N; Kumar P; Shanker K; Srivastava K; Sashidhara KV; Pal A
Phytomedicine; 2017 Jul; 30():1-9. PubMed ID: 28545664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
